We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Monitoring System Evaluated For Antiphospholipid Syndrome Patients

By LabMedica International staff writers
Posted on 03 Nov 2016
Print article
Image: The Protime InRhythm microcoagulation system kit (Photo courtesy of International Technidyne Corporation).
Image: The Protime InRhythm microcoagulation system kit (Photo courtesy of International Technidyne Corporation).
Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), or often also Hughes syndrome, is an autoimmune, hypercoagulable state caused by antiphospholipid antibodies.

APS provokes blood clots (thrombosis) in arteries and veins as well as pregnancy-related complications such as miscarriage, stillbirth, preterm delivery, and severe preeclampsia. Patients on anticoagulant therapy with vitamin K antagonists (VKA) need frequent International Normalized Ratio (INR) monitoring. The reliability of point-of-care (POC) devices for measuring INR needs rigorous evaluation, particularly in patients with APS.

Scientists at the University of Milan (Italy) compared a POC- INR device versus the laboratory INR measurement for blood samples from 29 APS-positive and 31 APS-negative patients consecutively enrolled. Chromogenic factor X assay was used to evaluate anticoagulation. Bland–Altman difference plot for paired INR (POC versus laboratory) was used to evaluate agreement between the device and the laboratory method. The device INR relationship with factor X chromogenic assay was evaluated by orthogonal regression analysis.

The team evaluated the accuracy of the ProTime InRhythm System (International Technidyne Corporation, Piscataway, NJ, USA), which consists of an instrument and disposable cuvettes. Each cuvette consists of two PT microchannels containing human recombinant thromboplastin to analyze a patient’s sample in duplicate to ensure accurate results, and a third internal control channel that is activated each time a test is performed to verify the integrity of the reagents and proper test procedure.

The scientists found that overall, 97% of the POC device INR measurements were similar to laboratory INR values with an absolute difference less than 0.4 units. Correlation coefficient for the device INR versus factor X was −0.69, (CI 95% −0.80 to −0.52). The authors concluded that The ProTime InRhythm System is an accurate point-of-care device for measuring INR also in patients with and without APS. The study was published in the October 2016 issue of the International Journal of Laboratory Hematology.

Related Links:
University of Milan
International Technidyne Corporation
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Coagulation Analyzer
CS-2400

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.